Literature DB >> 12413931

Pathology of borderline (low malignant potential) ovarian tumours.

Jeffrey D Seidman1, Brigitte M Ronnett, Robert J Kurman.   

Abstract

Recent studies suggest that the borderline group of ovarian tumours can be subclassified into benign and malignant neoplasms. The survival for patients with serous borderline tumours confined to the ovaries is virtually 100%. Patients with serous borderline tumours with invasive peritoneal implants, and with micropapillary serous carcinomas (a distinctive neoplasm previously included in the borderline category), have a 30-40% mortality rate and therefore these tumours are classified as carcinomas. After these neoplasms are excluded, the remaining advanced stage serous borderline tumours (those with non-invasive implants) have a survival rate of nearly 100% and should be considered benign. Similarly, nearly all mucinous borderline tumours reported to display aggressive behaviour have been associated with pseudomyxoma peritonei, a condition now known to be of appendiceal origin. The remaining mucinous borderline tumours are always confined to the ovaries and have a benign behaviour. Since borderline tumours can now be classified into benign and malignant types, the category has no further utility.

Entities:  

Mesh:

Year:  2002        PMID: 12413931     DOI: 10.1053/beog.2002.0300

Source DB:  PubMed          Journal:  Best Pract Res Clin Obstet Gynaecol        ISSN: 1521-6934            Impact factor:   5.237


  8 in total

1.  Mucinous borderline ovarian tumors: Analysis of 75 patients from a single center.

Authors:  Duygu Kavak Cömert; Işın Üreyen; Alper Karalok; Tolga Taşçı; Osman Türkmen; Reyhan Öcalan; Taner Turan; Gökhan Tulunay
Journal:  J Turk Ger Gynecol Assoc       Date:  2016-01-12

2.  Epithelial ovarian cancer: An overview.

Authors:  Arpita Desai; Jingyao Xu; Kartik Aysola; Yunlong Qin; Chika Okoli; Ravipati Hariprasad; Ugorji Chinemerem; Candace Gates; Avinash Reddy; Omar Danner; Geary Franklin; Anachebe Ngozi; Guilherme Cantuaria; Karan Singh; William Grizzle; Charles Landen; Edward E Partridge; Valerie Montgomery Rice; E Shyam P Reddy; Veena N Rao
Journal:  World J Transl Med       Date:  2014-04-12

Review 3.  The Putative Role of TP53 Alterations and p53 Expression in Borderline Ovarian Tumors - Correlation with Clinicopathological Features and Prognosis: A Mini-Review.

Authors:  Andrzej Semczuk; Marek Gogacz; Anna Semczuk-Sikora; Maciej Jóźwik; Tomasz Rechberger
Journal:  J Cancer       Date:  2017-08-22       Impact factor: 4.207

4.  Immunohistochemical profiling of benign, low malignant potential and low grade serous epithelial ovarian tumors.

Authors:  Véronique Ouellet; Tak Hay Ling; Karine Normandin; Jason Madore; Christian Lussier; Véronique Barrès; Dimcho Bachvarov; Claudine Rancourt; Patricia N Tonin; Diane M Provencher; Anne-Marie Mes-Masson
Journal:  BMC Cancer       Date:  2008-11-26       Impact factor: 4.430

5.  Gene expression profiling of epithelial ovarian tumours correlated with malignant potential.

Authors:  Susanne Warrenfeltz; Stephen Pavlik; Susmita Datta; Eileen T Kraemer; Benedict Benigno; John F McDonald
Journal:  Mol Cancer       Date:  2004-10-07       Impact factor: 27.401

6.  Increased chromosomal stability in cultures of ovarian tumours of low malignant potential compared to cystadenomas.

Authors:  J Yu; D Roy; A D Brockmeyer; L Dubeau
Journal:  Br J Cancer       Date:  2007-05-22       Impact factor: 7.640

7.  Borderline ovarian tumors: a study of 100 cases from a Tertiary Care Hospital.

Authors:  Ahmet Uysal; Semih Mun; Fatma Uysal; Murat Oztekin; Cem Büyüktosun; Salim Sehirali; Omer Başoğul; Cüneyt E Taner
Journal:  Contemp Oncol (Pozn)       Date:  2013-06-28

8.  The prevalence of malignant and borderline ovarian cancer in pre- and post-menopausal Chinese women.

Authors:  Fang Shen; Shouzhen Chen; Yifei Gao; Xujing Dai; Qi Chen
Journal:  Oncotarget       Date:  2017-08-22
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.